VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) is ticking higher in early trading Monday following reports that Qsymia prescriptions rose following the Thanksgiving holiday.
According to Bloomberg Industries-compiled data, prescriptions to the weight-loss drug rose 21 percent in the week ended November 29th.
BI thinks Thanksgiving boosted overall demand, with retail prescriptions rising 19 percent sequentially. Qsymia prescriptions fell 6 percent during the week of Thanksgiving.
Shares of VIVUS are indicated 2 percent higher Monday morning. Traders are likely to keep an eye on Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) following the news. Both are key players in the obesity pill game along with VIVUS.
According to Bloomberg Industries-compiled data, prescriptions to the weight-loss drug rose 21 percent in the week ended November 29th.
BI thinks Thanksgiving boosted overall demand, with retail prescriptions rising 19 percent sequentially. Qsymia prescriptions fell 6 percent during the week of Thanksgiving.
Shares of VIVUS are indicated 2 percent higher Monday morning. Traders are likely to keep an eye on Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) following the news. Both are key players in the obesity pill game along with VIVUS.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- Inter Parfums (IPAR) PT Lowered to $172 at Piper Sandler
- Acrivon Therapeutics Inc (ACRV) PT Raised to $30 at Piper Sandler
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
